返回
Prokidney Corp（PROK）價格
PROK 股價走勢圖
PROK 財務
Prokidney Corp
$2.14
-6.55%
$-0.14
收盤價：Jan 20, 16:00:00 GMT-5
$2.21
3.27%
$0.06
盤後：Jan 20, 20:00:00 GMT-5
關鍵數據
前收市價
$2.29
開盤價
$2.19
當日範圍
$2.12 - $2.24
52週區間
$0.46 - $7.13
交易量
1.3M
平均成交量
1.3M
每股盈餘 (TTM)
-0.54
股息收益率
--
市值
$664.8M
什麼是 PROK？
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.